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Introduction {#sec1}
============

Sexually reproductive diploid animals exhibit evolutionary advantages over asexual organisms due to meiosis and the combination of two haploid gametes from different genetic backgrounds ([@bib14], [@bib26]). Diploid genomes have allelic backups, but this hinders the elucidation of the gene function of recessive traits. Recently developed haploid cell lines, including near-haploid tumor cells ([@bib3], [@bib9]) and haploid embryonic stem cells (haESCs) ([@bib15], [@bib28]), greatly facilitate forward and reverse genetic screening in mammalian species ([@bib18]). It is easy to identify not only toxicant-targeting genes ([@bib6]) but also crucial genes regulating critical biological processes (such as differentiation \[[@bib17]\] or X chromosome inactivation \[[@bib23]\]) through high-throughput screening in haESCs. However, daily cultured haESCs tend to revert to diploid status, and periodic sorting for haploids is necessary, which hampers the application of these cell lines in genetic screening. In addition, haESCs undergo more severe diploidization during differentiation both *in vitro* and *in vivo*, making the derivation of haploid lineage-specific somatic cells very difficult ([@bib29]). Therefore, spontaneous diploidization of haESCs jeopardizes the exploration of the application of haploid technology in mammalian organ development or disease-related genetic screening despite their original single-genome status.

Many efforts have been made to clarify the mechanism underlying the diploidization of mammalian haESCs; however, no precise regulatory pathway has yet been found. A previous report showed that the reason for the diploidization of mouse haESCs was a mistake in their cell cycle rather than the fusion of two single haploid cells, as indicated by the coculturing of haESCs with different marker genes ([@bib16]). Thereafter, chemical compounds inhibiting cell-cycle-related proteins were introduced into the culture medium to reduce diploidization ([@bib12], [@bib34]), which still did not solve the problem completely. Single-cell dynamic analysis of mitosis in haESCs demonstrated that the metaphase of these cells was significantly longer than that of diploid ESCs ([@bib10]). Thus, delayed mitosis might be the main cause of self-diploidization in haESCs. In this case, time-consuming and complicated fluorescence-activated cell sorting (FACS) was necessary to maintain the haploidy of haESCs. Recent studies showed that knockout of *p53* ([@bib24]) or overexpression of *Dnmt3b* ([@bib13]) could stabilize the haploid genome and slow down self-diploidization. In particular, *p53*-null haESCs could sustain haploid status well both under daily culture and in cells converting to an extraembryonic cell fate ([@bib25]). *p53* is an essential gene related to the cell cycle, DNA damage, and other crucial biological processes ([@bib1], [@bib4], [@bib8]). Nevertheless, whether the *p53*-null mutation is beneficial for the maintenance of a haploid status during differentiation is still unknown. The exact mechanism by which *p53*-null reduces self-diploidization is also not clear.

In this study, we deleted *p53* in mouse parthenogenetic haESCs with the CRISPR/Cas9 system and performed differentiation both *in vitro* and *in vivo* to assess whether *p53*-null stabilized haploidy in the somatic stage. The results revealed that by deleting *p53*, haploid somatic cells could be easily obtained from differentiated haESCs. We further analyzed global transcriptome data and found that genes regulating apoptosis were the main reason for diploidization during the differentiation of haESCs.

Results {#sec2}
=======

*p53*-Null HaESCs Maintain Haploidy Much More Stably Compared with Wild-Type HaESCs under Long-Term Culture {#sec2.1}
-----------------------------------------------------------------------------------------------------------

We generated two mouse parthenogenetic haESC lines from chemically activated oocytes according to a previous protocol ([@bib30]). These haESCs showed a standard mouse ESC morphology ([Figure S1](#mmc1){ref-type="supplementary-material"}A) and grew well with the haploid genome assisted by FACS ([Figure S1](#mmc1){ref-type="supplementary-material"}B). To introduce *p53* mutations in haESCs, we designed two Cas9-mediated *p53*-single guide RNA (sgRNA) vectors to perform electroporation ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Two days after transfection, approximately 58.6% of the analyzed cells were Cas9-GFP-positive ([Figure S1](#mmc1){ref-type="supplementary-material"}D), and these cells were harvested for further culturing. We randomly picked three subclones from the sorted cultures and determined whether they were gene edited. All three subclones (*p53* KO-1, *p53* KO-2, and *p53* KO-3) carried different mutations in the *p53* gene according to DNA sequencing ([Figure 1](#fig1){ref-type="fig"}A). The T7EN1 cleavage assay results also confirmed this ([Figure 1](#fig1){ref-type="fig"}B). To assess whether the P53 protein was lost, we performed western blotting in *p53* KO-1, *p53* KO-2, *p53* KO-3, wild-type (WT) haESCs, and WT diploid ESCs (WT-diESCs). The results demonstrated that P53 was absent in all three *p53*-KO haESC lines ([Figure 1](#fig1){ref-type="fig"}C).Figure 1*p53* Deletion in haESC and DNA Analysis during Proliferation(A). *p53*-deleted genotypes in subclones *p53* KO-1, *p53* KO-2, and *p53* KO-3.(B) T7ENI cleavage analysis of the *p53*-KO lines *p53* KO-1, *p53* KO-2, and *p53* KO-3. Cleaved products (red arrowheads) indicate the presence of mutations.(C) Western blotting to detect P53 in WT-diESCs, WT-haESCs, *p53* KO-1, *p53* KO-2, and *p53* KO-3 cells. GAPDH was used as a loading control.(D) Expression levels of pluripotent, *p53*-related, and cell-cycle-related genes (*Oct4*, *Nanog*, *p53*, *p21*, *CyclinB*, *Cdk2*, and *MAPK11*) in WT-haESCs, *p53* KO-1, *p53* KO-2, and *p53* KO-3 cells determined by qPCR (n = 3 independent experiments). Data presented as mean ± SEM. t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(E) DNA content analysis of *p53*-KO haESCs during culture on day 0, day 14, and day 21 without sorting, with WT-haESCs as a control. The percentages of the 1n (G~0~/G~1~) peak in WT-haESCs were 27.4%, 9.33%, and 2.4%, respectively; in *p53* KO-1 cells, 23.5%, 22.8%, and 21.4%, respectively; in *p53* KO-2 cells, 23.6%, 21.1%, and 20.9%, respectively; in *p53* KO-3 cells, 23.7%, 21.5%, and 20.2%, respectively.(F) Percentage of GFP^+^ cells in *p53* KO-1-*p53* OE cells after transfection. WT-haESCs without transfection were used as a negative control.(G) Bright-field (BF) and FITC images of *p53* KO-1-*p53* OE cells, Scale bar, 100 μm.(H) Expression levels of *p53* in WT-haESCs, *p53* KO-1-Vector, *p53* KO-1, and *p53* KO-1-*p53* OE cells determined by qPCR (n = 3 independent experiments). Data presented as mean ± SEM. t test: ^∗∗∗^p \< 0.001.(I) Percentages of haploids in *p53* KO-1, *p53* KO-1-Vector, WT-haESCs, and *p53* KO-1-*p53* OE cells 10 days after sorting. Nearly 44% of sorted cells remained in haploidy in *p53* KO-1 and *p53* KO-1-Vector group, whereas WT-haESCs and *p53* KO-1-*p53* OE exhibited only 29% staying as haploid cells (n = 3 independent experiments). Data presented as mean ± SEM. t test: ^∗∗∗^p \< 0.001.See also [Figure S1](#mmc1){ref-type="supplementary-material"} and [Table S4](#mmc1){ref-type="supplementary-material"}.

To determine whether *p53* mutation affects the pluripotency of haESCs, we examined specific markers and alkaline phosphatase activity in *p53*-KO haESCs. Positivity was observed not only for pluripotency markers (OCT4, NANOG, and SSEA-1) but also for alkaline phosphatase in *p53*-KO haESCs ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F). Karyotype analysis showed that most chromosome spreads of *p53*-KO haESCs contained 20 chromosomes ([Figure S1](#mmc1){ref-type="supplementary-material"}G). Next, we analyzed pluripotent genes and *p53*-related genes in *p53*-KO haESCs by real-time PCR with WT-haESCs as a control. The expression levels of pluripotent markers (*Oct4* and *Nanog*) and *Cyclin B* did not change significantly in *p53*-KO haESCs compared with WT-haESCs. However, expression of *p53* and *p21* decreased, meanwhile *Cdk2* and *MAPK11* increased significantly in all three *p53*-KO haESC lines ([Figure 1](#fig1){ref-type="fig"}D). This result indicated that *p53* mutations did not affect pluripotency but do affect *p53*-related genes, including some cell-cycle genes. Since *p53* deletion increased haploidy maintenance in the ESC stage, as previously described, we tested whether *p53*-KO haESCs exhibited advantages in haploidy maintenance in daily culture without sorting for 3 weeks. There was still a high percentage of haploid cells remaining in the 1n peak (G~0~/G~1~ phase) of *p53*-KO haESCs (*p53* KO-1, 21.4%; *p53* KO-2, 20.9%; *p53* KO-3, 20.2%), whereas the percentage of the 1n peak (G~0~/G~1~ phase of haploid cells) in WT-haESCs decreased to 2.4% ([Figure 1](#fig1){ref-type="fig"}E). Here, we chose *p53* KO-1 (the most stable) for subsequent experiments. We designed *p53* overexpression (*p53* OE) vectors ([Figure S1](#mmc1){ref-type="supplementary-material"}H) and transferred them into *p53* KO-1 cells having a high proportion of haploids, with an empty vector as control. After transfection, transfected cells expressing exogenous GFP (a GFP cassette was included in the *p53* OE vector or empty vector) were enriched for GFP and haploidy double-positive cells by FACS ([Figures 1](#fig1){ref-type="fig"}F and 1G). Real-time PCR result revealed that *p53* OE-haESCs (*p53* KO-1-*p53* OE) had re-expressed *p53* gene compared with WT-haESCs, *p53* KO-1, and *p53* KO-1-vector ([Figure 1](#fig1){ref-type="fig"}H). Western blotting analysis further confirmed this result ([Figure S1](#mmc1){ref-type="supplementary-material"}I). Thereafter, we checked the haploidy-maintaining ability among *p53* KO-1, *p53* KO-1-vector, WT-haESCs, and *p53* KO-1-*p53* OE cells without sorting for 10 days (all the samples started as 100% of haploid cells). DNA-content analysis demonstrated that only *p53* KO-1 and *p53* KO-1-vector were able to maintain haploidy stably in this period, whereas *p53* KO-1-*p53* OE and WT-haESCs diploidized to some degree ([Figure 1](#fig1){ref-type="fig"}I). The rescue of *p53* expression in *p53*-KO haESCs made them unable to sustain the phenotype of stable haploidy any longer, which proved that *p53* was the main trigger of the diploidization phenomenon. As *Cdk2* and *MAPK11* (two important cell-cycle genes) were upregulated in *p53*-KO haESCs according to the above qPCR analysis, we conducted overexpression (OE) of *Cdk2* and *MAPK11* separately in WT-haESCs to address whether either of the two genes would affect the process of diploidization. Although the OE-haESCs showed upregulation of *Cdk2* and *MAPK11* independently ([Figures S1](#mmc1){ref-type="supplementary-material"}J and S1K), neither of them obtained an advantage in maintaining haploidy like *p53*-KO in long-term cell culture ([Figure S1](#mmc1){ref-type="supplementary-material"}L).

*p53*-Null HaESCs Differentiate Reliably with a Haploid Genome *In Vitro* {#sec2.2}
-------------------------------------------------------------------------

To examine the haploid-maintaining ability of *p53*-KO haESCs during differentiation *in vitro*, we performed differentiation of *p53*-KO haESCs at different stages. Standard embryoid bodies (EBs) formed ([Figure 2](#fig2){ref-type="fig"}A), and 29.7% of haploid cells (at G~0~/G~1~ phase) were observed in 7-day EBs from *p53*-KO haESCs ([Figure 2](#fig2){ref-type="fig"}B). The expression levels of pluripotency genes and specific genes of the three germ layers showed that the haploid EBs had differentiated beyond the ESC stage ([Figure 2](#fig2){ref-type="fig"}C). Although WT parthenogenetic haESCs were not able to remain in the epiblast stem cell-like cell (EpiLC) stage with a haploid genome ([@bib16]), *p53*-KO haESCs differentiated into haploid EpiLCs (haEpiLCs) quite easily and stably sustained haploidy ([Figures 2](#fig2){ref-type="fig"}D and 2E). The primed state haEpiLCs expressed pluripotent markers such as OCT4 and NANOG ([Figure 2](#fig2){ref-type="fig"}F). Besides, naive-primed distinguishing marker TFE3 ([@bib2]) was located in the cytoplasm of haEpiLCs ([Figure 2](#fig2){ref-type="fig"}G), demonstrating that *p53*-KO haEpiLCs could remain in the epiblast stage with a single genome in the presence of basic fibroblast growth factor (bFGF) and activin A. The expression levels of specific genes further proved that these haploid cultures expressed primed stage genes (*FGF5* and O*tx2*), rather than naive genes (*Rex1* and *Klf4*), with WT-haESCs and WT epiblast stem cells (WT-EpiSCs) as controls ([Figures 2](#fig2){ref-type="fig"}H and 2I). To assess differentiation potentials of haEpiLCs, we induced neural differentiation according to a previous protocol ([@bib39]). Around 7--10 days post differentiation, NESTIN- and TUJ1-positive cells were observed in the cell cultures ([Figure 2](#fig2){ref-type="fig"}J), indicating that haEpiLCs possessed pluripotency to differentiate to the next stage.Figure 2*In Vitro* Differentiation of *p53*-KO haESCs(A) Morphology of 7-day haEBs derived from *p53* KO-1 cells. Scale bar, 100 μm.(B) DNA-content analysis of 7-day haEBs derived from *p53* KO-1 cells. The percentage of the 1n (G~0~/G~1~) peak in haEBs was 21.7%.(C) Expression levels of pluripotency and differentiation genes (*Rex1*, *Hand1*, *Cdx2*, *Fgf5*, *Nestin*, and *T*) in haEBs and haESCs determined by qPCR (n = 3 independent experiments). Data presented as mean ± SEM. t test: ^∗∗∗^p \< 0.001.(D) Morphology of haEpiLCs derived from *p53* KO-1 cells. Scale bar, 100 μm.(E) DNA-content analysis of haEpiLCs derived from *p53* KO-1 cells. The percentage of the 1n (G~0~/G~1~) peak in haEpiLCs was 21.8%.(F) Immunofluorescence of OCT4 and NANOG in haEpiLCs derived from *p53* KO-1 cells. DNA was stained with DAPI. Scale bar, 50 μm.(G) Immunofluorescence of TFE3 in haEpiLCs derived from *p53* KO-1 cells and haESCs. DNA was stained with DAPI. Scale bar, 50 μm.(H) Expression levels of pluripotency genes (*Oct4*, *Nanog*, *Rex1*, and *Klf4*) in WT-haESCs, WT-EpiSCs, and haEpiLCs determined by qPCR (n = 3 independent experiments). Data presented as mean ± SEM. t test: ^∗∗∗^p \< 0.001.(I) Expression levels of EpiSC-specific marker genes (*Fgf5* and *Otx2*) in WT-haESCs, WT-EpiSCs and haEpiLCs determined by qPCR (n = 3 independent experiments). Data presented as mean ± SEM. t test: ^∗∗∗^p \< 0.001.(J) Immunostaining of NESTIN and TUJ1 in 10-day differentiation cell cultures of haEpiLCs. Scale bar, 50 μm.(K) Morphology of haNSCLCs derived from *p53* KO-1 cells. Scale bar, 100 μm.(L) DNA-content analysis of haNSCLCs derived from *p53* KO-1 cells. The percentage of the 1n (G~0~/G~1~) peak in haNSCLCs was 28.5%.(M) Immunofluorescence of OCT4 and NANOG in haNSCLCs. DNA was stained with DAPI. Scale bar, 50 μm.(N) Immunofluorescence of neural stem cell-specific markers in haNSCLCs, PAX6, SOX1, and NESTIN. DNA was stained with DAPI. Scale bar, 50 μm.(O) Immunostaining of oligodendrocytes (O4) and astrocytes (GFAP) derived from *p53* KO-1. Scale bar, 50 μm.(P) Immunostaining of neuronal specific markers (MAP2, NEUN, and TUJ1) in neurons derived from *p53* KO-1. Scale bar, 50 μm.See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Table S4](#mmc1){ref-type="supplementary-material"}.

Although haploid neural progenitor cells ([@bib6]) and haploid neurons ([@bib36]) could be detected transiently, it is very difficult to obtain stable haploid neural stem cell-like cells (NSCLCs) by traditional methods. Whether *p53*-KO haESCs could differentiate into somatic stages and maintain haploidy required further investigation. We introduced endogenous NSCLC-specific *Pax6*-GFP into *p53*-KO haESCs according to our previous protocol ([@bib20]). We performed neural differentiation of *p53* KO-1 cells and found that there were 22.3% of *Pax6*-GFP-positive cells among the differentiated derivatives ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Interestingly, there were 6.2% of *Pax6*-GFP-positive cells in the 1n peak, whereas there were 27.8% of *Pax6*-GFP-negative cells in the 1n peak ([Figure S2](#mmc1){ref-type="supplementary-material"}B). These findings demonstrated that diploidization occurred but was slowed down during the differentiation of *p53*-KO haESCs. Haploid and *Pax6*-GFP double-positive cells were enriched by FACS to derive haNSCLCs for further culture. The haNSCLCs showed the standard neural stem cell morphology when cultured under adherent conditions ([Figure 2](#fig2){ref-type="fig"}K), presenting the ability to aggregate into neural spheres ([Figure S2](#mmc1){ref-type="supplementary-material"}C). DNA analysis revealed that the haNSCLCs could stably maintain haploidy during proliferation ([Figure 2](#fig2){ref-type="fig"}L). Next, we examined pluripotent and neural stem cell-specific markers in haNSCLCs by immunostaining. Pluripotent markers (OCT4 and NANOG) were absent in haNSCLCs ([Figure 2](#fig2){ref-type="fig"}M). Positivity for PAX6, SOX1, and NESTIN was observed in adherent haNSCLCs ([Figure 2](#fig2){ref-type="fig"}N) and their neural spheres ([Figure S2](#mmc1){ref-type="supplementary-material"}D). To assess the differentiation potential of haNSCLCs, we performed neural lineage specification. The results showed that glial cells (O4 and glial fibrillary acidic protein \[GFAP\] positive) and multiple neurons (MAP2, NEUN, and TUJ1 positive) could be generated from haNSCLCs ([Figures 2](#fig2){ref-type="fig"}O and 2P). In another parallel experiment, we analyzed DNA contents of glial mixture and neuronal mixture independently. There was 2.0% of glial mixture and 4.5% of neuronal mixture remaining in the 1n peak, respectively ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F), indicating that haNSCLCs possessed multipotency for neural lineages with a haploid genome.

Haploid Cells Can Contribute to Chimeric Fetuses and Teratomas upon *p53* Knockout {#sec2.3}
----------------------------------------------------------------------------------

The finding that *p53*-KO haESCs showed excellent haploidy maintenance during differentiation *in vitro* led to the further investigation of whether they presented the same advantages during differentiation *in vivo*. We microinjected GFP-labeling *p53-*KO haESCs into blastocysts to construct chimeric embryos. The reconstructed embryos were transferred to the oviducts of 0.5 days post coitum (dpc) pseudopregnant mice. Chimeric embryonic day 6.5 (E6.5) embryos from GFP-labeling *p53-*KO haESCs and GFP-labeling WT-haESCs were obtained ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A). Around 17.2% cells of chimeric E6.5 1\# embryo and 55.5% cells of chimeric E6.5 2\# embryo generated from *p53*-KO haESCs microinjection were GFP-positive cells ([Table S1](#mmc1){ref-type="supplementary-material"}). The haploid cells in the 1n peak of *p53*-KO haESCs-chimeric E6.5 embryos (*p53* KO-1, chimeric 1\#, 28.5%; *p53* KO-2, chimeric 2\#, 24.5%) were much higher than that in WT-haESCs-chimeric E6.5 embryo (WT-haESCs-chimeric, 4.7%) ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}B; [Table S1](#mmc1){ref-type="supplementary-material"}), demonstrating that *p53-*KO haESCs could contribute to an epiblast stage with a high proportion of haploid status. For chimeric E8.5 embryos, 12.4% cells of 1\# embryo and 37.6% cells of 2\# embryo from *p53*-KO haESCs microinjection were GFP-positive cells ([Table S1](#mmc1){ref-type="supplementary-material"}). However, chimeric E8.5 embryos from *p53-*KO haESCs were abnormal ([Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}C), possibly due to the high contribution of haploid cells (a haploid genome might not support full development) or deficiency of *p53*, with approximately 25% of these cells (*p53* KO-1, chimeric 1\#, 25.3%; *p53* KO-2, chimeric 2\#, 24.3%) remaining in the 1n peak ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}D). To address the identity of these haploid cells from E8.5 embryos, we harvested them by FACS and performed qPCR analysis. Compared with WT-haESCs, the sorted haploid cells barely expressed any of the pluripotent markers (*Oct4*, *Nanog*, *Stella*, *Rex1*, and *Klf4*), demonstrating that they were indeed differentiated cells ([Figure 3](#fig3){ref-type="fig"}E). Thus, *p53-*KO haESCs could differentiate into a somite stage without diploidization. To investigate the effect of *p53* deletion on development, we microinjected GFP-labeling *p53-*KO diploid ESCs into blastocysts as a parallel experiment. Interestingly, chimeric E8.5 embryos from *p53-*KO diploid ESCs were normal ([Figure 3](#fig3){ref-type="fig"}F), with GFP cells (24.9% in 1\# and 40.3% in 2\#) contributing to the chimeric E8.5 embryos ([Table S1](#mmc1){ref-type="supplementary-material"}). Furthermore, abnormal chimeric E10.5 embryos were also able to be obtained ([Figures 3](#fig3){ref-type="fig"}G and [S3](#mmc1){ref-type="supplementary-material"}E). The percentages of GFP cells in chimeric E10.5 1\# and 2\# embryos from *p53*-KO haESCs microinjection were 1.6% and 3.3%, respectively ([Table S1](#mmc1){ref-type="supplementary-material"}). According to DNA analysis, there were still around 22% of haploid cells in 1n peak (*p53* KO-1, chimeric 1\#, 21.4%; *p53* KO-2, chimeric 2\#, 22.3%) from E10.5 GFP-positive cells ([Figures 3](#fig3){ref-type="fig"}H and [S3](#mmc1){ref-type="supplementary-material"}F), indicating that *p53-*KO haESCs could further differentiate in a haploid genome with limited development potentials.Figure 3*In Vivo* Analysis of *p53*-KO haESCs(A) Morphology of chimeric embryos at E6.5 derived from GFP-labeling WT-haESCs and *p53* KO-1 cells. Scale bar, 100 μm. WT-E6.5 embryo was used as a control.(B) DNA-content analysis of GFP^+^ cells and GFP^−^ cells in chimeric E6.5 embryos derived from GFP-labeling WT-haESCs and *p53* KO-1 cells. The percentages of the 1n (G~0~/G~1~) peak in GFP^+^ cells from *p53* KO-1 E6.5 and WT-haESCs E6.5 were 28.5% and 4.7%, respectively.(C) Morphology of chimeric embryo at E8.5 derived from GFP-labeling *p53* KO-1 cells. WT-E8.5 embryo was used as a control.(D) DNA-content analysis of GFP^+^ cells and GFP^−^ cells in chimeric E8.5 embryo derived from GFP-labeling *p53* KO-1 cells. The percentage of the 1n (G~0~/G~1~) peak from *p53* KO-1 chimeric E8.5 GFP^+^ cells was 25.3%.(E) Expression levels of pluripotency genes (*Oct4*, *Nanog*, *Stella*, *Rex1*, and *Klf4*) in chimeric E8.5 haploid cells from GFP^+^ cells, with WT-haESCs as a loading control (n = 3 independent experiments). Data presented as mean ± SEM. t test: ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(F) Morphology of chimeric embryos at E8.5 derived from GFP-labeling *p53* KO-diploid cells.(G) Morphology of chimeric embryos at E10.5 derived from GFP-labeling *p53* KO-1 cells. WT E10.5 was used as a control.(H) DNA-content analysis of GFP^+^ cells and GFP^−^ cells in chimeric E10.5 embryo derived from GFP-labeling *p53* KO-1 cells. The percentage of the 1n (G~0~/G~1~) peak from *p53* KO-1 chimeric E10.5 GFP^+^ cells was 21.4%.(I) Teratoma formed from *p53* KO haESCs was identified by H&E staining. Scale bar, 100 μm. The tissues shown were gut epithelium (endoderm), muscle (mesoderm), and neural tissue (ectoderm).(J) DNA-content analysis of teratoma. The percentage of the 1n (G~0~/G~1~) peak from all the tissue was 3.1%.(K) Expression levels of pluripotent genes (*Oct4*, *Nanog*, *Stella*, *Rex1*, and *Klf4*) in the 1n cells sorted from teratoma determined by qPCR, with WT-haESCs as a loading control (n = 3 independent experiments). Data presented as mean ± SEM. t test: ^∗∗∗^p \< 0.001.See also [Figure S2](#mmc1){ref-type="supplementary-material"}; [Tables S1](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

To check the pluripotency of *p53-*KO haESCs to form the three germ layers, we injected approximately 1 × 10^7^ *p53* KO-1 cells under the skin of severe combined immunodeficiency (SCID) mice. Three weeks later, a standard teratoma formed ([Figures S3](#mmc1){ref-type="supplementary-material"}G and S3H) and was divided into two parts. Histological analysis was performed on one part, and DNA-content analysis was performed on the other. Gut epithelium, muscle, and neural tube tissues, representing the three germ layers, were observed by H&E staining ([Figure 3](#fig3){ref-type="fig"}I). According to the DNA-content analysis, 3.1% haploid cells (1n peak) still existed in the 3-week teratoma, demonstrating that the *p53*-KO haESCs show a powerful ability to maintain haploidy *in vivo* ([Figure 3](#fig3){ref-type="fig"}J). The haploid cells from teratoma were also sorted by FACS and checked by qPCR. The result showed that the haploid cells in teratoma did not express the pluripotent marker genes (*Oct4*, *Nanog*, *Stella*, *Rex1*, and *Klf4*), indicating that they had entered a differentiated state instead of a pluripotent state ([Figure 3](#fig3){ref-type="fig"}K).

Transcriptome Analysis of *p53*-KO HaESCs {#sec2.4}
-----------------------------------------

To determine why *p53*-KO haESCs show great advantages in haploidy maintenance, we compared the transcriptomes between *p53*-KO haESCs and WT-haESCs by RNA-sequencing (RNA-seq) analysis. The results revealed a very high correlation (R^2^ = 0.9947) between *p53*-KO haESCs (*p53* KO-1, *p53* KO-2, and *p53* KO-3) and WT-haESCs (three independent WT-haESC lines) ([Figure 4](#fig4){ref-type="fig"}A). According to comprehensive summaries with all expression data ([Tables S2](#mmc2){ref-type="supplementary-material"} and [S3](#mmc3){ref-type="supplementary-material"}), there were 2,785 differentially expressed genes (p \< 0.01, fold change \>2) between *p53*-KO haESCs and WT-haESCs, which were further analyzed to elucidate the reason of haploidy stabilization. Hierarchical clustering (heatmap) showed the top 50 differentially expressed genes between *p53*-KO haESCs and WT-haESCs, considering a fold change of 2.0 and p \< 0.05 ([Figure S4](#mmc1){ref-type="supplementary-material"}A and [Table S2](#mmc2){ref-type="supplementary-material"}). These differentially expressed genes were mainly related to the extracellular matrix and basic development according to gene ontology (GO) analysis ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C). GO analysis data further indicated that most of the upregulated genes were correlated with male meiotic nuclear division, Piwi-interacting RNA metabolic process, and other biological processes, whereas the downregulated genes were related to vasculature development and extracellular matrix organization ([Figure 4](#fig4){ref-type="fig"}B). Since *p53* is a very important gene involved in multiple biological processes, including DNA-damage repair, cell-cycle arrest, and apoptosis ([@bib11]), we analyzed the expression of specific genes involved in these processes between *p53*-KO haESCs and WT-haESCs in volcano plots of p values (−log~10~ scale) versus fold changes (log~2~ scale). Interestingly, there were several differentially expressed genes related to apoptosis identified between the two groups ([Figure 4](#fig4){ref-type="fig"}C). However, we did not observe distinctly expressed genes related to the cell cycle or DNA damage in the RNA-seq data ([Figure 4](#fig4){ref-type="fig"}C). As we also found that the *p53*-KO haESCs showed better survival ability during differentiation compared with WT-haESCs *in vitro* (data not shown), we assessed carefully the differentially expressed genes correlated with apoptosis. *TP73* (*p73*, also known as *Trp73*), *Phlda3*, *Cdkn1a*, and *Bbc3* (downstream target genes of *p53*) were significantly downregulated in *p53*-KO haESCs ([Figure 4](#fig4){ref-type="fig"}D) and were listed as the top four downregulated genes in *p53*-KO haESCs related to apoptosis. We further detected the expression levels of some target genes of *p53* related to apoptosis by qPCR and found that only *p73* and *Bbc3* were significantly downregulated ([Figure 4](#fig4){ref-type="fig"}E).Figure 4Transcriptome of *p53*-KO haESCs(A) Scatterplot of log~2~ transformed average gene expression profiles. Global gene expression of three *p53*-KO haESCs (*p53* KO-1, *p53* KO-2, and *p53* KO-3) and three WT-haESC lines (WT-haESCs-1, WT-haESCs-2, and WT-haESCs-3) were analyzed by scatterplot (R^2^ is the Pearson correlation coefficient).(B) Enriched gene ontologies of upregulated and downregulated genes in *p53*-KO haESCs.(C) Volcano plot depicting the differential expression analysis between WT-haESCs and *p53*-KO haESCs. The higher location of the point of the gene, the more significant the difference. Highlighted points indicate genes correlated with apoptosis, cell cycle, and DNA damage, respectively, considering a fold change of 2.0 and p \< 0.05.(D) Top ten genes correlated with apoptosis in the differential expression analysis between WT-haESCs and *p53* KO haESCs.(E) Expression levels of apoptosis-related genes (*p73*, *Phlda3*, *Bbc3*, and *Bax*) and a proliferation-related gene (*MAPK11*) in WT-haESCs and *p53*-KO haESCs determined by qPCR (n = 3 independent experiments). Data presented as mean ± SEM. t test: ^∗^p \< 0.05, ^∗∗∗^p \< 0.001.(F) Caspase-3 activity of *p53* KO-1, *p53* KO-2, and *p53* KO-3 cells, with WT-haESCs as a control (n = 3 independent experiments). Data presented as mean ± SEM. t test: ^∗∗∗^p \< 0.001.See also [Figure S4](#mmc1){ref-type="supplementary-material"} and [Tables S2](#mmc2){ref-type="supplementary-material"}, [S3](#mmc3){ref-type="supplementary-material"}, and [S4](#mmc1){ref-type="supplementary-material"}.

To address whether apoptosis was the main reason for the diploidization of haESCs, we assessed the survival rate of *p53*-KO haESCs 24 h after sorting for haploids compared with WT-haESCs. Nearly 70.5% of the sorted cells survived and expanded in the *p53*-KO group, whereas in the control group this percentage was only 52.9% ([Figure S4](#mmc1){ref-type="supplementary-material"}D). As caspase-3 is a key molecule in the process of apoptosis ([@bib32]), we measured the caspase-3 activity between *p53*-KO haESCs and WT-haESCs after sorting. The caspase-3 activities in *p53* KO-1, *p53* KO-2, and *p53* KO-3 were significantly decreased compared with that in WT-haESCs ([Figure 4](#fig4){ref-type="fig"}F). In summary, apoptosis of *p53*-KO haESCs was reduced in daily culture and FACS processes.

*p73* Is a Major Target of *p53*-Regulating Diploidization {#sec2.5}
----------------------------------------------------------

To find out more about apoptosis-related gene-regulating diploidization, we designed *p73* and *Bbc3* knockout vectors ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B) and transfected them separately into WT-haESCs to introduce gene editing. Among the 60 randomly picked subclones of the *p73*-edited group, 25 subclones maintained haploidy ([Figure S5](#mmc1){ref-type="supplementary-material"}C). We sequenced 11 subclones with high percentages of haploid cells and found that four of them were *p73*-KO cells ([Figure 5](#fig5){ref-type="fig"}A). To assess whether the P73 protein was lost, we performed western blotting in *p73* KO-1, *p73* KO-2, *p73* KO-3, WT-haESCs, and diploid ESCs. The results demonstrated that P73 was absent in three *p73*-KO haESC lines ([Figure 5](#fig5){ref-type="fig"}B). However, in the *Bbc3*-edited group, 18 out of 60 randomly selected subclones exhibited haploid cells, 9 of which showed a high percentage of haploids, which were sequenced and did not contain a *Bbc3* mutation ([Figure S5](#mmc1){ref-type="supplementary-material"}C). We randomly checked two diploidized subclones by sequencing and found *Bbc*3 mutations ([Figure S5](#mmc1){ref-type="supplementary-material"}D). DNA-content analysis again confirmed that the *Bbc3* mutant subclones were diploid, without any haploid cells ([Figure S5](#mmc1){ref-type="supplementary-material"}E). Notably, this result indicated that *p73* alone was the key regulator of diploidization, rather than *Bbc3*. We further assessed whether *p73*-KO haESCs also showed advantages in haploidy maintenance similar to those of *p53*-KO haESCs. The results demonstrated that *p73*-KO haESCs exhibited better proliferation ability after sorting ([Figure S5](#mmc1){ref-type="supplementary-material"}F) and a lower rate of diploidization during long-term culture ([Figure 5](#fig5){ref-type="fig"}C) compared with WT-haESCs. The caspase-3 activity in *p73* KO-1, *p73* KO-2, and *p73* KO-3 was much lower than that in WT-haESCs, suggesting that apoptosis could be inhibited by *p73*-KO ([Figure 5](#fig5){ref-type="fig"}D). Next, we examined the expression of *p53*-targeted genes related to apoptosis in *p73*-KO haESCs (*p73* KO-1, *p73* KO-2 and *p73* KO-3) and WT-haESCs and did not find any significant differences in the downstream gene ([Figure 5](#fig5){ref-type="fig"}E). This result indicated that *p73* played a crucial role in affecting diploidization without interacting with its upstream genes, including *p53*.Figure 5*p73* Is a Major Target of *p53-*Regulating Diploidization(A) *p73*-deleted genotypes in haESCs by DNA sequencing.(B) Western blot to detect P73 in *p73* KO-1 cells, *p73* KO-2 cells, *p73* KO-1 cells, WT-haESCs, and WT-diESCs. GAPDH was used as a loading control.(C) Progression of the percentage of haploid cells in the *p73*-KO haESCs and WT-haESCs for 14 days, 28 days, and 35 days after sorting (n = 3 independent experiments). Data presented as mean ± SEM. t test: ^∗∗∗^p \< 0.001.(D) Caspase-3 activity of *p73* KO-1, *p73* KO-2, and *p73* KO-3 cells, with WT-haESCs as a control (n = 3 independent experiments). Data presented as mean ± SEM. t test: ^∗∗∗^p \< 0.001.(E) Expression levels of apoptosis-related genes (*p53*, *Bbc3*, and *Bax*) and proliferation-related gene *MAPK11* in *p73* KO-1, *p73* KO-2, and *p73* KO-3 haESCs determined by qPCR, with WT-haESCs as a control (n = 3 independent experiments). Data presented as mean ± SEM. t test: ^∗^p \< 0.05, ^∗∗^p \< 0.01.See also [Figure S5](#mmc1){ref-type="supplementary-material"} and [Table S4](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

Haploidy in lower organisms, including yeast, is fairly stable, which makes haploid individuals a powerful tool for genetic engineering ([@bib5]). Medaka fish haESCs also show durable haploidy in both undifferentiated and differentiated statuses, despite being vertebrate species ([@bib38]). However, mammalian haESCs tend to revert to diploidy under daily culture or differentiation, making complicated and frequent sorting of haploids necessary. Although haNSCLCs have been obtained by an optimized epiblast-based method ([@bib31]) or by introducing a ROCK inhibitor (Y27632) into the culture medium ([@bib12]), these cells are not easy to handle, and the underlying mechanisms require further investigation. Our findings provide a simple strategy for deriving multiple haploid somatic cells by knocking out a single gene (*p53*-KO or *p73*-KO). We find that reduced apoptosis may be a major reason why *p53*-KO haESCs stably maintain haploidy. Additionally, knockout of *p73*, a target of *p53*, can also stabilize haploidy in haESCs.

Although *p53* or *p73* deficiency can promote haploidy maintenance in mouse haESCs, whether this phenomenon is applicable to other species remains unknown. Previous studies reported that primate haESCs maintain haploidy more stably than rodent haESCs ([@bib28], [@bib37]), and whether the mechanisms involved correlate with *p53* or *p73* warrants further investigation. Another study showed that although rhesus monkey haESCs maintained haploidy well in the ESC state, they underwent severe diploidization during differentiation for reasons related to apoptosis ([@bib35]). Therefore, apoptosis may be the major cause of the diploidization of mammalian haploid cells. Generally, both haESCs and haploid somatic cells do not exhibit growth properties equivalent to those of their diploid counterparts ([@bib24]). Our data revealed that *p53*-KO or *p73*-KO haESCs survived better after FACS ([Figure S4](#mmc1){ref-type="supplementary-material"}D) and regained their proliferative ability faster ([Figure S5](#mmc1){ref-type="supplementary-material"}F) than WT-haESCs. Previous studies have indicated that some haESCs experience cell-cycle errors such as mitosis escape, resulting in diploidization ([@bib10], [@bib12]). According to our RNA-seq data, however, *p53*-KO haESCs did not show significant changes in the expression of cell-cycle-related genes ([Figure 4](#fig4){ref-type="fig"}C). We propose that the stabilization of haploidy in *p53*-KO haESCs depended on a reduction in apoptosis instead of regulation of the cell cycle. Nevertheless, both *p53* and *p73* are essential genes involved in many pathways, including key cell-cycle checkpoints ([@bib22], [@bib33]). The exact mechanism by which *p53*-KO or *p73*-KO haESCs avoid mitosis escape has not yet been clarified.

Due to diploidization, complicated and time-consuming FACS purification is necessary for haploidy maintenance. Non-staining sorting methods have been introduced to enrich haploids ([@bib7], [@bib27]), but their efficiency cannot be guaranteed. In our study, *p53*-KO or *p73*-KO haESCs could maintain haploidy without sorting for at least 3 weeks, which facilitates the expansion of large-scale haploid cell cultures rapidly for high-throughput genetic screening. However, previous reports demonstrated that *p53*-deficiency diploid ESCs showed limited pluripotency ([@bib19], [@bib21]). In our study, *p53*-KO haESCs also showed nearly 2,800 differentially expressed genes from WT-haESCs at global transcriptome level. This indicated that there might be potential restriction of *p53*-KO haESCs in differentiation, which needs further investigation. Nevertheless, *p53*-KO haESCs could contribute to chimeras (up to E10.5) and teratomas in haploid status, which would mean that haploid somatic cells could be derived in a rigorous way *in vivo*, thus expanding the application of such a haploid system for lineage-specific genetic screening.

Experimental Procedures {#sec4}
=======================

Transfection {#sec4.1}
------------

To obtain *p53*-KO haESC lines, we electroporated approximately 4 × 10^6^ WT-haESCs with PX461-sgRNA1 (3 μg) and PX461-sgRNA2 (3 μg), using a Neon (Invitrogen) electroporator at 1,400 V for 10 ms with three pulses. GFP-positive cells were sorted by FACS 2 days post electroporation. For the overexpression of *p53*, a combination of 2 μg of the *PBase* plasmid (SBI, PB210PA-1) and 6 μg of the overexpressing (or empty *piggyBac* control) plasmid were electroporated into 4 × 10^6^ *p53*-KO haESCs using the same electroporating conditions described above. After transfection for 4--5 days, GFP and haploidy double-positive cells were sorted for subsequent experiments. Overexpression of *Cdk2* and *MAPK11* plasmids and *PBase* plasmid were transfected into WT-haESCs, respectively. After transfection for 4--5 days, GFP and haploidy double-positive cells were sorted for subsequent experiments. To obtain GFP-labeling cell lines, we electroporated a combination of 2 μg of the *PBase* plasmid (SBI, PB210PA-1) and 6 μg of the *piggyBac-*GFP plasmid into 4 × 10^6^ *p53*-KO haESCs, *p53*-KO diESCs, or WT-haESCs, independently.

Differentiation of *p53*-KO haESCs {#sec4.2}
----------------------------------

To detect the DNA contents of haploid embryonic bodies (haEBs) derived from *p53*-KO haESCs, we cultured the cells with Ndiff medium (Takara, Y40002) in noncoated Petri dishes (Falcon) for 7 days. EB aggregates were then dissociated with 0.05% trypsin/EDTA (Gibco, 25300062), and the DNA content was analyzed by FACS. To generate haEpiLCs, we added *p53* KO-1 cells to the wells of a 12-well plate coated with human fibronectin (Yeasen, 40105ES08) in EpiSC medium (Ndiff medium \[Takara, Y40002\] containing 20 ng/mL activin A \[PeproTech, 120-14E-100\] and 12 ng/mL bFGF \[PeproTech, AF-100-18B-100\]). The medium was changed every day, and standard EpiLC colonies emerged 2--3 days later. Fully grown haEpiLCs were passaged with 0.05% trypsin/EDTA and further cultured in EpiSC medium. After sorting for haploid cells 2--3 times (around 14 days), DNA content of haEpiSCs was analyzed. To generate haNSCLCs, we first established a *Pax6*-GFP *p53* KO-1 cell line as described previously ([@bib20]). Four-day EB aggregates derived from *Pax6*-GFP *p53* KO-1 cells were then plated in fibronectin-precoated Petri dishes. After 9 days, *Pax6*-GFP-positive cells were sorted. The DNA content of the *Pax6*-GFP-positive/negative cells was then analyzed. Sorted *Pax6*-GFP-positive haploid cells were further cultured in N2B27 medium supplemented with 10 ng/mL EGF (PeproTech, AF-315-09-100) and 10 ng/mL bFGF (PeproTech, AF-100-18B-100) for proliferation.

For neuronal differentiation, haNSCLCs were plated into dishes precoated with poly-D-lysine (Sigma, P4957) and laminin (Sigma, L2020) and cultured in N2B27 medium supplemented with 20 ng/mL brain-derived neurotrophic factor (PeproTech, AF-450-02) and 20 ng/mL neurotrophin-3 (PeproTech, AF-450-03) to generate neurons. After 2 weeks, the differentiated haNSCLCs were examined for the expression of neuronal (TUJ1, MAP2, and NEUN) and oligodendroglial (O4) markers. For astrocyte differentiation, haNSCLCs were exposed to 1% fetal bovine serum and 10 ng/mL bone morphogenetic protein 4 (PeproTech, AF-120-05ET) in N2B27 medium for 5 days, followed by GFAP staining.

Chimeric Assay and Teratoma Formation {#sec4.3}
-------------------------------------

E6.5, E8.5, and E10.5 chimeric embryos were generated by injecting GFP-labeling *p53*-KO haESCs, *p53*-KO diploid ESCs, or WT-haESCs cells into CD-1 background blastocysts. Reconstructed embryos were transferred to the oviducts of pseudopregnant CD-1 mice at 0.5 dpc. At E6.5, E8.5, and E10.5, pseudopregnant mice were sacrificed to dissect chimeric fetuses. Chimeric embryos were trypsinized and GFP-positive and DNA-content analysis performed by FACS.

For teratoma analysis, approximately 1 × 10^7^ *p53* KO-1 cells were injected subcutaneously into the limbs of 8-week-old male SCID mice. Fully formed teratomas were dissected 3 weeks later, then fixed in 4% paraformaldehyde, embedded in paraffin, sectioned, and stained with H&E for further analysis. Alternatively, fully formed teratomas were dissected to analyze the DNA contents.

Data and Code Availability {#sec4.4}
--------------------------

The Gene Expression Omnibus accession number for the RNA-seq data reported in this paper is GEO: [GSE148118](ncbi-geo:GSE148118){#intref0010}.

A complete description of the methods can be found in [Supplemental Information](#appsec1){ref-type="fn"}.
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